Summary
Intuitive Surgical, Inc. (ISRG) announced a significant regulatory milestone on July 8, 2004, with the FDA granting clearance for its da Vinci Surgical System for cardiac revascularization procedures. This marks a crucial expansion of the da Vinci system's approved applications, moving beyond its previous uses into the highly significant field of cardiac surgery. The clearance is a testament to the system's demonstrated safety and efficacy in a new, complex surgical area, which is expected to open up substantial new market opportunities for the company.
Key Highlights
- 1FDA clearance for da Vinci Surgical System for cardiac revascularization procedures granted on July 7, 2004.
- 2This clearance represents a significant expansion of the approved uses for Intuitive Surgical's flagship product.
- 3Cardiac revascularization is a major surgical field, suggesting a substantial new addressable market for the da Vinci system.
- 4The FDA clearance validates the system's capabilities for complex cardiac procedures.
- 5This development is expected to drive future revenue growth and market penetration for Intuitive Surgical.
Frequently Asked Questions
The primary significance is the FDA's clearance of the da Vinci Surgical System for cardiac revascularization procedures. This allows Intuitive Surgical to market and sell its system for use in a new and important surgical specialty.
Cardiac revascularization refers to surgical procedures performed to restore normal blood flow to an area of the heart muscle that has been reduced by ischemic heart disease. Coronary artery bypass grafting (CABG) is a common example.
This clearance is expected to significantly expand Intuitive Surgical's market reach by opening up the large and complex field of cardiac surgery. It could lead to increased sales of the da Vinci system and its associated instruments and services, driving revenue growth.
The filing specifically mentions clearance for 'cardiac revascularization.' It is important to refer to the detailed FDA clearance documentation or company statements for the precise scope of approved indications within cardiac surgery.